BioDelivery Sciences International, Inc. et al v. Chemo Research, S.L. et al
| BioDelivery Sciences International, Inc. and Arius Two, Inc. |
| Chemo Research, S.L., Insud Pharma S.L.U., IntelGenx Technologies Corp. and Xiromed, LLC |
| IntelGenx Corp. |
| 1:2022cv01196 |
| September 12, 2022 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on November 10, 2022. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 12 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Xiromed, LLC. (Gaza, Anne) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent IntelGenX Technologies Corp. for IntelGenx Corp.; Other Affiliate atai Life Sciences N.V. for IntelGenx Technologies Corp. filed by IntelGenx Corp., IntelGenx Technologies Corp.. (Gaza, Anne) |
| Filing 10 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Grupo Insud GmbH for Insud Pharma S.L.U. filed by Insud Pharma S.L.U.. (Gaza, Anne) |
| Filing 9 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Insud Pharma S.L.U. for Chemo Research, S.L. filed by Chemo Research, S.L.. (Gaza, Anne) |
| Filing 8 ANSWER to #1 Complaint, , COUNTERCLAIM against Arius Two, Inc., BioDelivery Sciences International, Inc. by Insud Pharma S.L.U., Xiromed, LLC, Chemo Research, S.L., IntelGenx Technologies Corp., IntelGenx Corp..(Gaza, Anne) |
| Filing 7 WAIVER OF SERVICE returned executed by BioDelivery Sciences International, Inc., Arius Two, Inc.: For Chemo Research, S.L. waiver sent on 9/27/2022, answer due 11/28/2022; Insud Pharma S.L.U. waiver sent on 9/27/2022, answer due 11/28/2022; IntelGenx Corp. waiver sent on 9/27/2022, answer due 11/28/2022; IntelGenx Technologies Corp. waiver sent on 9/27/2022, answer due 11/28/2022; Xiromed, LLC waiver sent on 9/27/2022, answer due 11/28/2022. (Tigan, Jeremy) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 6 Summonses Issued (please complete the top portion of the form and print out for use/service). (apk) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Collegium Pharmaceutical, Inc. for BioDelivery Sciences International, Inc.; Corporate Parent BioDelivery Sciences International, Inc. for Arius Two, Inc. filed by Arius Two, Inc., BioDelivery Sciences International, Inc. (apk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,147,866 B2 ;9,655,843 B2 ;9,901,539 B2. (apk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/1/2022. Date of Expiration of Patent: SEE ANDA FORM.Thirty Month Stay Deadline: 2/1/2025. (apk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Chemo Research, S.L., Insud Pharma S.L.U., IntelGenx Corp., IntelGenx Technologies Corp., Xiromed, LLC ( Filing fee $ 402, receipt number ADEDC-3957341.) - filed by BioDelivery Sciences International, Inc., Arius Two, Inc. (Attachments: #1 Exhibit A-C, #2 Civil Cover Sheet)(apk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
